Plain-English translation of NCT07000084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two treatment approaches for bladder cancer that has returned after previous BCG therapy. Half of participants will receive the standard treatment (BCG alone), while the other half will receive combined with BCG. Researchers want to see if adding this medication helps prevent cancer from coming back.
BCG is the standard treatment for high-grade bladder cancer, but some patients' cancers return after this therapy. This trial tests whether combining the medication with BCG can better control the disease and reduce the need for bladder removal surgery.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard BCG treatment or BCG combined with . Both groups will receive weekly treatments for 6 weeks, followed by additional treatments at months 3, 6, and 12. Throughout the study, you'll have regular cystoscopy exams (camera procedure to look inside your bladder), biopsies, imaging scans, and blood and urine tests to monitor your response and watch for any side effects. The entire study lasts about 12 months of active treatment with follow-up visits.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States